What factors affect the midazolam dose?
Midazolam is an extremely strong and fast -acting benzodiazepine drug. Due to the extremely short half -life in the body, it is usually not used as a treatment of clinical distress disorders, like most other benzodiazepine drugs. Instead, midazolam is usually used for procedural sedation, preoperative sedation and general anesthesia, especially if the side effect of the drug is the anti -medical amnesia. Drugs are sometimes used as an acute treatment of seizures in pediatric patients at the site of rectally administered diazepam. Each of these applications requires administration of a different mezolam dosage, with other adaptations according to the patient's age, kidney health, liver function, discardation, susceptibility to respiratory depression and existing drug regime.
Adult patients who require preoperative sedation should have a midzolam as an intramuscular injection between 0.07 and 0.08 mg to 2.2 lbs (1 kg) of body weight approximately one hour before surgery. If surgery requires sedation at VRemaining and patient does not receive any other depressions of the central nervous system as pre-medication, then the corresponding midazolam dose is between 1.0 and 2.5 mg intravenously within two minutes in 1 mg/ml in adults. The dose may be increased in 5.0 mg increments every two or more minutes.
pediatric patients require significantly lower midazolam dose. Initial intramuscular injections for preoperative sedation should be between 0.1 and 0.15 mg to 2.2 pounds (1 kg) of body weight, not to exceed 10 mg, except for unique circumstances and with careful monitoring. Preoperative sedative doses were provided up to 0.5 mg per kg.
Patients aged six and 12 years old who receive a medicine to cause conscious sedaciig 0.025 to 0.05 mg to £ 2.2 (1 kg) weight up to a maximum of 0.4 mg to 2.2 pounds (1 kg) or a total of 10 mg. Those between six months and six years of age should be given 0.05 to 0 instead, 1 mg to £ 2.2 (1 kg), up to a maximum of 0.6 mg to £ 2.2 (1 kg), or a total of 6 mg. Patients up to six months of age should be administered carefully, starting with a low dosage of midazolam, which is carefully adjusted to achieve the desired sedation level. Premature infants should not be administered intravenously, because this form of drug contains benzyl alcohol associated with fatal "gas syndrome" in this population.
It may be necessary to adjust the dosage to suit patients with a deterioration of kidney function, as it can prolong half the life of the midazolam in the body, increasing the time required for recovery. Patients with reduced liver function will require lower doses. As a result, it is essential for these patients to receive extremely low initially, with dosing only carefully increased during careful monitoring.